🏭 Viking Pharmaceutical partners with CordenPharma for production
Concerns about VK2735 not being able to be manufactured en masse are put to rest.
One of the most promising new GLP1 receptor agonists of 2024 is Viking Pharmaceutical’s VK2735 — a drug so new that it doesn’t yet have a brand name.
The key worry with VK2735 was that it would be hard to produce it — but recently Viking Therapeutics has a secured a partnership that should prevent that.